Previously submitted to: JMIR Mental Health (no longer under consideration since Dec 05, 2024)
Date Submitted: Dec 2, 2024
Open Peer Review Period: Dec 5, 2024 - Dec 5, 2024
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Continuous glucose monitoring as a tool for psychological support - exploring metabolic control and psychological well-being after initial cgm implementation in adults with type 1 diabetes
ABSTRACT
Background:
January 2023 marked a significant breakthrough for type 1 diabetes treatment in Poland, as the reimbursement of intermittently scanned CGM (isCGM)/continuous glucose monitoring (CGM) was initiated for individuals aged 26 and older.
Objective:
Assessment of changes in quality of life, metabolic control, fear of hypoglycemia and selected psychological parameters after implementation of the isCGM/CGM in people with type 1 diabetes (PwT1D) aged 26 and above.
Methods:
The study involved 57 PwT1D from five Polish diabetology centers. To be included in the study, each participant had to be at least 26 years old, have a minimum of two years of diabetes history, and be treated with multiple daily injections or a personal insulin pump. The exclusion criterion from the study was the use of isCGM/CGM for more than two weeks prior to the study. Participants completed a set of validated questionnaires: Hypoglycemia Fear Survey-II (FSH-II); Diabetes Distress Scale (DDS); Perceived Stress Scale (PSS10); Diabetes Treatment Satisfaction Questionnaire status version (DTSQs); World Health Organization Well-Being Index (WHO-5); Problem Areas in Diabetes (PAID); Diabetes Burnout Questionnaire (DBQ), and sociodemographic survey, downloaded 14-day pump/glucometer data, and underwent HbA1c measurement during visits. After 3 months of CGM use, participants repeated assessments, isCGM/CGM reports were also re-evaluated.
Results:
Slightly more than half of the participants were male (n=29, 50.9%). The median age of the group was 37.5 years (IQR 29.5-46.0 years), while the median duration of diabetes was 16 years (IQR 29.5-46.0 years). After 3 months of using CGM, individuals reported higher treatment satisfaction measured by DTSQs (median 27.0 vs 30.0, p=0.01) and less frequently experienced unacceptably high glycemia (median 4.0 vs 3.0, p<0.001). Well-being assessment according to WHO-5 was also higher (mean 13.1 vs 14.3, p=0.04), and the level of diabetes burnout measured by DBQ (median 3.0 vs 1.0, p<0.001), fear of hypoglycemia assessed by HFS-II (median 41.0 vs 30.5, p=0.03) significantly decreased. Diabetic distress measured by means of total score of DDS lowered from 2.7 to 2.0 (p=0.001), with decreased scores in emotional burden, regimen distress and interpersonal distress subscales. Participants scored also lower on PAID upon follow up (median 36.8 vs 21.3, p=0.001). However, the average stress level measured by PSS-10 did not change (p=0.94). Regarding glycemic control, the percentage of HbA1c after three months of using the system was significantly lower (7.3 vs 7.1%, p=0.01).
Conclusions:
The use of isCGM/CGM, even during relatively short observation, leads to improved quality of life, reduced fear of hypoglycemia and diabetes burnout, and lower HbA1c levels in PwT1D over the age of 26 who were naïve to this technology. These psychological and metabolic benefits support expanding isCGM and CGM use to a broader range of patients. Clinical Trial: NA
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.